A combination of dabrafenib with trametinib was approved by the FDA for treatment of pediatric patients 1 year and older with low-grade glioma & BRAF V600E mutation who require systemic therapy.
Chris Ryan
Advertisement
Articles by Chris Ryan
Advertisement
Latest Updated Articles
FDA Approves Drug Combo for Young Glioma PatientsMarch 17th 2023
Advertisement
Advertisement
Trending on Drug Topics
1
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
How mRNA and Protein-Based COVID-19 Vaccines Work
4
Updated Guideline Refines Approach to Migraine Prevention in Adults
5